35
Views
3
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Contribution of celiac disease autoantibodies to the disease process

&
Pages 151-154 | Published online: 10 Jan 2014
 

Abstract

Evaluation of: Teesalu K, Panarina M, Uibo O, Uibo R, Utt M. Autoantibodies from patients with celiac disease inhibit transglutaminase 2 binding to heparin/heparan sulfate and interfere with intestinal epithelial adhesion. Amino Acids doi:10.1007/s00726-011-1020-1 (2011) (Epub ahead of print).

Transglutaminase 2 is a multifunctional protein involved in cellular adhesion. Moreover, transglutaminase 2 has been identified as the autoantigen in celiac disease, and in untreated celiac disease, in addition to being present in the serum, the transglutaminase 2-targeted autoantibodies are bound to their antigen in the basement membrane underlining the small-bowel mucosal epithelium. Furthermore, the disease-specific transglutaminase 2-targeted autoantibodies have been experimentally shown to exert various biological effects on different cell types. Using Caco-2 intestinal epithelial cells, it has now also been demonstrated that serum transglutaminase 2-targeted autoantibodies from untreated celiac patients inhibit the adhesion of these cells. These findings provide an important direction for future research to improve our general understanding of celiac disease pathogenesis and especially the role of the disease-specific autoantibodies during the progression of the disorder.

Financial & competing interests disclosure

The authors have received financial support from the Academy of Finland, the Sigrid Juselius Foundation, the Foundation for Pediatric Research, the Competitive Research Funding of Tampere University Hospital and the European Commission IAPP grant TRANSCOM (contract number PIA-GA-2010-251506). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.